<code id='74DE6F1FBD'></code><style id='74DE6F1FBD'></style>
    • <acronym id='74DE6F1FBD'></acronym>
      <center id='74DE6F1FBD'><center id='74DE6F1FBD'><tfoot id='74DE6F1FBD'></tfoot></center><abbr id='74DE6F1FBD'><dir id='74DE6F1FBD'><tfoot id='74DE6F1FBD'></tfoot><noframes id='74DE6F1FBD'>

    • <optgroup id='74DE6F1FBD'><strike id='74DE6F1FBD'><sup id='74DE6F1FBD'></sup></strike><code id='74DE6F1FBD'></code></optgroup>
        1. <b id='74DE6F1FBD'><label id='74DE6F1FBD'><select id='74DE6F1FBD'><dt id='74DE6F1FBD'><span id='74DE6F1FBD'></span></dt></select></label></b><u id='74DE6F1FBD'></u>
          <i id='74DE6F1FBD'><strike id='74DE6F1FBD'><tt id='74DE6F1FBD'><pre id='74DE6F1FBD'></pre></tt></strike></i>

          leisure time

          leisure time

          author:focus    Page View:54292
          UnitedHealth Group
          UnitedHealth Group’s Optum will pay $3.3 billion total for the home health giant Amedisys. Jim Mone/AP

          Home health and hospice chain Amedisys has chosen a new corporate owner.

          Amedisys and UnitedHealth Group’s Optum agreed to a deal Monday in which UnitedHealth will pay $101 per share in cash for Amedisys, totaling $3.3 billion. UnitedHealth’s latest offer is $1 per share higher than what it proposed in its unsolicited buyout offer a few weeks ago.

          advertisement

          Option Care Health, a company that delivers intravenous medicines and mails health care supplies to people’s homes, originally offered to acquire Amedisys in May in an all-stock deal. However, the attractiveness of that deal deteriorated after Option Care’s stock price plummeted soon after the company made its bid.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          leisure time

          Activists slam private health insurers over coverage restrictions
          Activists slam private health insurers over coverage restrictions

          ProtestorsoutsideAmerica'sHealthInsurancePlansheadquarters.CourtesyPeople'sActionWASHINGTON—Hun

          read more
          Pfizer highlights cancer drugs it thinks could reignite investor interest
          Pfizer highlights cancer drugs it thinks could reignite investor interest

          AscreenattheNewYorkStockExchangelastNovember.MichaelM.Santiago/GettyImagesPfizerspentmorethanfourhou

          read more
          Moonlake's readout produced a cash windfall. Risks remain
          Moonlake's readout produced a cash windfall. Risks remain

          MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

          read more

          FDA's Pazdur wants cancer trials to range beyond China alone

          RichardPazdur,right,alsospokeabouttheFDA'suseofacceleratedapproval.MeganBearderPhotographyCHICAGO— T